PharmaTutor (September- 2014)
ISSN: 2347 - 7881
(Volume 2, Issue 9)
Received On: 14/06/2014; Accepted On: 25/06/2014; Published On: 01/09/2014
AUTHORS: V. Sravanthi*1, Mayure vijay kumar1, Donthineni Kalyan2, C.P.Meher1, G.J.Finny1
1Department of pharmaceutical chemistry, Maheshwara College of Pharmacy
2Department of Pharmaceutical Analysis, Saraswathi College of Pharmaceutical Sciences.
Isnapur chitkul ‘X’ road, Patancheru, Hyderabad-502307
*v.sravanthi27@gmail.com
ABSTRACT:
Candida albicans are the most effective organism that makes quite an yeast infection to form a inflammation in the different parts of the body like oral, vaginal, hepatic, renal etc…, During the infection of Candidiasis there are less chances of human death can occur, but in patient with damaged immune systems there is a chance of death, but to the Candidiasis flow to the blood streams and kills. In this review the full outline of the Candidiasis and the types and medication are put forth to be aware on the diseases caused by Candidiasis. According to FDA approval, the Ketoconazole is the first-line drug used for the treatment of the different types of Candidiasis.
How to cite this article: V Sravanthi, VK Mayure, K Donthineni, CP Meher, GJ Finny; A Review on Candidiasis: Types and Medications; PharmaTutor; 2014; 2(9); 36-45
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1.Mocroft A, Oancea C, van Lunzen J, et al. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol 2005; 100: 1446-54.
2.Chan KCW, Wong KH, Lee SS. HIV Infection in Women: the Hong Kong Experience to date. First Annual Scientific Meeting, Hong Kong Society for Infectious Disease. Hong Kong, 1997.
3.Manfredi R, Calza L, Chiodo F. Dual Candida albicans and Cryptococcus neoformans fungaemia in an AIDS presenter: a unique disease association in the highly active antiretroviral therapy (HAART) era. J Med Microbiol 2002; 51:1135-7.
4.Garbino J, Kolarova L, Lew D, Hirschel B, Rohner P. Fungemia in HIV-infected patients: a 12-year study in a tertiary care hospital. AIDS Patient Care STDS 2001; 15: 407-10.
5.Kerawala C, Newlands C (editors).Oral and maxillofacial surgery. Oxford: Oxford University Press. 2010; pp. 446, 447.
6.Treister NS, Bruch JM. Clinical oral medicine and pathology. New York: Humana Press. 2010; pp. 19, 21, 92, 93.
7.Rhodus, NL. "Treatment of oral candidiasis."Northwest dentistry Mar–Apr 2012, 91 (2): 32–3.
8.Soames JV, Southam JC, JV. Oral pathology (3rd ed.). Oxford: Oxford Univ. Press.1999; pp. 147, 193–200.
9.Cernea P, Crepy C, Kuffer R, Mascaro JM, Badillet G, Marie JL. Aspects peu connus de candidosis buccales. Les Candidases à foyers multiples de la cavité buccale. Rev Stomatol (Paris) 1965; 66:103–138.
10.Cawson RA, Lehner T. Chronic hyperplastic candidosis-candidal leukoplakia. Br J Dermatol N 1968; 80:9–16.
11.Holmstrup P, Besserman M. Clinical, therapeutic and pathogenic aspects of chronic oral multifocal candidiasis. Oral Surg Oral Med Oral Pathol, 1983; 56:388–395.
12.Bouquot, Brad W. Neville, Douglas D. Damm, Carl M. Allen, Jerry E. Oral & maxillofacial pathology (2nded.). Philadelphia: W.B. Saunders. 2002; pp. 192–194.
13.Tyldesley, Anne Field, Lesley Longman in collaboration with William R. Tyldesley's Oral medicine (5th ed.). Oxford: Oxford University Press.2003; pp. 35–40.
14.Manfredi, M; Polonelli, L; Aguirre-Urizar, J; Carrozzo, M; McCullough, "Urban legends series: oral candidosis.". Oral diseases. Aug 14, 2012.
15.Scully, Crispian. Oral and maxillofacial medicine: the basis of diagnosis and treatment (2nd ed.). Edinburgh: Churchill Livingstone. 2008; pp. 201–203.
16.Brocklehurst P; Tickle, M; Glenny, AM; Lewis, MA; Pemberton, MN; Taylor, J; Walsh, T; Riley, P; Yates, JM. "Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)." In Brocklehurst, Paul. The Cochrane database of systematic reviews 9; Sep 12, 2012
17.Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. Dermatology: 2-Volume Set. St. Louis: Mosby, 2009.
18. Scully, Crispian. Oral and maxillofacial medicine: the basis of diagnosis and treatment (2nd ed.). Edinburgh: Churchill Livingstone.2008; pp. 196–198.
19.James, William D.; Berger, Timothy G.; et al. Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier.2006.
20.James, William D.; Berger, Timothy G.; et al. Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier.2006; p. 309.
21.Sobel, JD. "Vulvovaginal candidosis.". Lancet, 9 June 2007; 369 (9577): 1961–71.
22.Workowski KA, Berman SM. "Sexually transmitted diseases treatment guidelines, 2006".MMWR Recomm Rep 55 , August 2006 ;(RR-11): 1–94.
23.Ilkit, M; Guzel, AB. "The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective". Critical reviews in microbiology, August 2011; 37 (3): 250–61.
24.Habif, T. Clinical Dermatology: A color guide to diagnosis and therapy. 3rd edition. Mosby, 1996.
25. Holmes, K., Sparling, P., Stamm, W., Piot, P., Wasserheit, J., Corey, L., Cohen, M., Watts, H. Sexually transmitted disease (4th ed). Toronto, ON: McGraw Hill Medical. 2008.
26. McMillan, A., Young, H., Ogilvie, M., Scott, G. Clinical Practice in Sexually Transmissible Infections. Saunders: London. 2002.
27.Mimidis, K; Papadopoulos, V; Margaritis, V; Thomopoulos, K; Gatopoulou, A; Nikolopoulou, V; Kartalis, G. "Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present?".International journal of clinical practice, Feb 2005; 59 (2): 210–3.
28. Hamza OJM, Matee MIN, Brüggemann RJM, et al. "Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, double-blind, double-dummy trial". Clin Infect Dis, 2008; 47 (10): 1270–1276.
29.James, William D.; Berger, Timothy G. et al; Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. 2006.
30.Rigopoulos D, Larios G, Gregoriou S, Alevizos A. "Acute and chronic paronychia". Am Fam Physician, Feb 2008; 77 (3): 339–46.
31. Rockwell PG. "Acute and chronic paronychia". Am Fam Physician, Mar 2001; 63 (6): 1113–6.
32.Ritting, AW; O'Malley, MP; Rodner, CM. "Acute paronychia.". The Journal of hand surgery, May 2012; 37 (5): 1068–70;
33.James, William D.; Berger, Timothy G.; et al. Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. 2006.
34.Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. Dermatology: 2-Volume Set. St. Louis: Mosby. 2007.
35. Strous, Rael D.; Edelman, Morris C. "Eponyms and the Nazi Era: Time to Remember and Time for Change". Israel Medical Association Journal, 2007; 9: 207–214.
36.James, William D.; Berger, Timothy G.; et al. Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. 2006.
37.Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. Dermatology: 2-Volume Set. St. Louis: Mosby. 2007; p. 1135.
38.Westerberg D, Voyack MJ. "Onychomycosis: Current Trends in Diagnosis and Management". Am Fam Physician (Review), Dec 2013; 88 (11): 762–70.
39.James, William D.; Berger, Timothy G. Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier.
40. James, William D.; Berger, Timothy G.; et al. Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. 2006.
41.Jump up^ Schiefer HG. "Mycoses of the urogenital tract". Mycoses 40 Suppl 2: 33–6. 1997.
42.de Repentigny, L., D. Lewandowski, and P. Jolicoeur. Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin. Microbiol. 2004; Rev.17:729-759.
43.Richards, M. J., J. R. Edwards, D. H. Culver, and R. P. Gaynes. Nosocomial infections in combined medical-surgical intensive care units in the United States.Infect. Control Hosp. Epidemiol. 2000; 21:510-515.
44.Lundstrom T, Sobel J. Nosocomial candiduria: a review. Clin Infect Dis2001; 32:1602–1607.
45.Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887–892.
46.Zaoutis T, Candidemia in children, Curr Med Res Opin. pub med. 2010 Jul; 26(7):1761-8
47.Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.
48.Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafin. Arch Dermatol 1997; 133:1317-8.
49.Azoulay E1, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Orgeas M, Cohen Y, Mourvillier B,Schlemmer B; Outcomerea Study Group. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia, PUBMED, Chest. 2006 Jan; 129(1):110-7.
50.Pfizer Australia Pty Ltd. Diflucan (Australian Approved Product Information). West Ryde (NSW): Pfizer Australia; 2004
51.Rossi S, editor. Australian Medicines Handbook2006. Adelaide: Australian Medicines Handbook; 2006.
52.Hammond, S.M. "Biological activity of polyene antibiotics.". Progress in medicinal chemistry. 1977; 14 (105-179).
53."FDA approved package insert".
54."Clotrimazole (Oral)". Lexicomp Online. Retrieved 17 April 2014.
55."Clotrimazole: MedlinePlus Drug Information". The American Society of Health-System Pharmacists, Inc. Retrieved 17 April 2014.
56.Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. CLSI Document M27-A3, Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA,19087-1898 USA, 2008
57."WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
58.Vogl S, Picker P, Mihaly-Bison J, Fakhrudin N, Atanasov AG, Heiss EH, Wawrosch C, Reznicek G, Dirsch VM, Saukel J, Kopp B. Ethnopharmacological in vitro studies on Austria's folk medicine - An unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs. J Ethnopharmacol.2013 Jun13.
59. webmd.com/drugs/drug-2768-Nystatin Triamcinolone
60.Rossi, S, ed. Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. 2013.
61.Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. "Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors". Antimicrobial Agents and Chemotherapy, June 2003; 47 (6): 1805–17.
62. Thienpont, D; Van Cutsem, J; Van Nueten, JM; Niemegeers, CJ; Marsboom, R. "Bilogical and toxicological properties of econazole, a broad-spectrum antimycotic". Arzneimittel-Forschung, 1975; 25 (2): 224–30.
63. Ju, Jiang; Tsuboi, Ryoji ; Kojima, Yuko ; Ogawa, Hideoki (2005). "Topical application of ketoconazole stimulates hair growth in C3H/HeN mice". Journal of dermatology 32: 243–247.
64.Rapini, Ronald P. Bolognia, Jean L.; Jorizzo, Joseph L. Dermatology: 2-Volume Set. St. Louis: Mosby, 2007; p. 1867.
65.Noguchi, T.; Hashimoto, Y.; Miyazaki, K.; Kaji, A.; J. Pharm. Soc. Japan 1968, 88, 335
66.Callen JP, Hughes AP, Kulp-Shorten C "Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases". Arch Dermatol Sep2001; 137 (9): 1196–8.
.png)
